hst-2 Antibody

What is hST2 and what is its biological significance?

Suppression of Tumorigenicity 2 (ST2) functions as the receptor for interleukin-33 (IL-33) and is expressed on both hematopoietic and epithelial cells. It plays a critical role in mediating immune responses orchestrated by type I helper T cells. ST2 exists in two primary forms: a membrane-bound receptor (ST2L) localized to the cell surface, and a soluble form that circulates in peripheral blood functioning as a decoy receptor. The IL-33/ST2 system has been identified as crucial for Th2-driven pathologies and participates in the regulation of various inflammatory processes. Recent research has highlighted soluble ST2 as a potential biomarker for early diagnosis and treatment monitoring in cancer, pneumonia, and cardiovascular diseases .

How do monoclonal antibodies against hST2 function in research applications?

Monoclonal antibodies against hST2, such as clone HI436, are engineered to specifically recognize and bind to human soluble ST2 proteins. These antibodies enable researchers to detect, quantify, and study the expression and distribution of ST2 in various biological samples. The high specificity of monoclonal antibodies makes them valuable tools for experimental techniques including ELISA and immunofluorescence assays where precise detection of target proteins is essential .

What are the common experimental applications for anti-hST2 antibodies?

Anti-hST2 monoclonal antibodies are primarily utilized in enzyme-linked immunosorbent assays (ELISA) and immunofluorescence assays (IFA). These techniques allow researchers to quantify hST2 levels in biological samples and visualize its cellular localization, respectively. The applications extend to studying the role of ST2 in Th2-mediated immune responses, investigating inflammatory conditions, and exploring biomarker potential in various pathological states including cancer and cardiovascular diseases .

What factors should be considered when designing experiments with anti-hST2 antibodies?

When designing experiments with anti-hST2 antibodies, researchers should consider:

• Antibody specificity: Ensure the antibody specifically recognizes human ST2 without cross-reactivity to other proteins.

• Sample preparation: Different applications require specific sample preparation methods to preserve the epitope structure recognized by the antibody.

• Antibody concentration: Optimal antibody dilution must be determined for each experimental system to maximize signal-to-noise ratio.

• Controls: Include positive controls (samples known to express ST2), negative controls (ST2-negative samples), and isotype controls (non-specific antibodies of the same isotype) to validate results.

• Detection systems: Select appropriate secondary antibodies or detection reagents compatible with the chosen experimental platform.

The quality and reliability of experimental results heavily depend on these considerations being properly addressed during experimental design .

How should researchers optimize ELISA protocols using anti-hST2 antibodies?

ELISA optimization with anti-hST2 antibodies involves systematic optimization of multiple parameters:

• Coating concentration: Determine the optimal concentration of capture antibody (typically 1-10 μg/ml) for coating plates.

• Blocking buffer selection: Test different blocking reagents (BSA, casein, non-fat milk) to minimize non-specific binding.

• Sample dilution series: Prepare multiple dilutions of samples to ensure measurements fall within the linear range of the standard curve.

• Antibody titration: Perform a dilution series of detection antibody to identify the concentration that maximizes specific signal while minimizing background.

• Incubation conditions: Optimize incubation times and temperatures for each step.

• Washing protocol: Determine the number and volume of washes needed between steps to reduce background without compromising signal intensity.

• Standard curve preparation: Use recombinant hST2 protein to generate a reliable standard curve for accurate quantification.

A properly optimized ELISA protocol will yield reproducible results with high sensitivity and specificity for hST2 detection .

What methodological considerations are important for immunofluorescence assays with anti-hST2 antibodies?

For successful immunofluorescence assays with anti-hST2 antibodies, researchers should address these methodological aspects:

• Fixation method: Select appropriate fixation reagents (paraformaldehyde, methanol, acetone) that preserve antigen structure while maintaining cellular morphology.

• Permeabilization: Optimize detergent concentration (Triton X-100, Tween-20, saponin) to allow antibody access to intracellular targets without excessive cell damage.

• Antigen retrieval: Determine if methods like heat-induced epitope retrieval or enzymatic digestion are necessary to expose masked epitopes.

• Antibody dilution: Titrate primary and secondary antibodies to identify optimal concentrations that maximize specific signal while minimizing background.

• Blocking parameters: Optimize blocking buffer composition and incubation time to reduce non-specific binding.

• Counterstaining: Select appropriate nuclear or cellular counterstains that do not interfere with hST2 detection.

• Mounting media: Choose mounting media compatible with fluorophores used for detection.

• Microscopy settings: Adjust exposure times, gain, and other parameters to capture true signal while avoiding autofluorescence.

These considerations help ensure that immunofluorescence assays provide accurate visualization of hST2 distribution within cells or tissues .

How can researchers address weak or absent signal when using anti-hST2 antibodies?

When confronted with weak or absent signals when using anti-hST2 antibodies, researchers should systematically troubleshoot the following:

• Antibody activity: Verify antibody functionality by testing with positive control samples known to express hST2.

• Epitope integrity: Ensure sample preparation methods haven't destroyed or masked the target epitope; consider alternate fixation or antigen retrieval protocols.

• Antibody concentration: Increase antibody concentration or incubation time to enhance signal intensity.

• Detection system sensitivity: Upgrade to more sensitive detection systems (e.g., amplification steps, brighter fluorophores, higher-affinity secondary antibodies).

• Sample quality: Assess sample integrity and protein degradation; use fresh samples when possible.

• Technical execution: Review every step of the protocol for potential technical errors during execution.

• Expression levels: Consider that target protein may be expressed at levels below detection limits; concentrate samples if possible.

Systematic evaluation of these factors often reveals the source of signal problems and allows for targeted protocol adjustments .

What strategies help resolve non-specific binding or high background with anti-hST2 antibodies?

To resolve non-specific binding or high background issues when working with anti-hST2 antibodies, researchers should implement these strategies:

• Optimize blocking: Increase blocking reagent concentration or test alternative blocking agents to more effectively mask non-specific binding sites.

• Adjust antibody concentration: Dilute primary and secondary antibodies further to reduce non-specific interactions.

• Enhance washing procedures: Increase wash duration, frequency, or stringency (higher salt concentration or mild detergents).

• Pre-adsorb antibodies: Incubate antibodies with samples known to lack the target but contain potential cross-reactive proteins.

• Use additives in buffers: Include carrier proteins (BSA), non-ionic detergents, or specific blocking peptides in antibody diluents.

• Test alternative antibody clones: Different monoclonal antibodies may offer improved specificity for the same target.

• Evaluate secondary antibody: Ensure secondary antibody specificity and consider using cross-adsorbed or highly specific versions.

• Reduce autofluorescence: For IF applications, use specific reagents to quench autofluorescence from tissues.

Implementing these approaches systematically can significantly improve signal-to-noise ratio and experimental specificity .

How can researchers use anti-hST2 antibodies to investigate the IL-33/ST2 axis in disease models?

Researchers investigating the IL-33/ST2 axis in disease models can employ anti-hST2 antibodies in several sophisticated approaches:

• Neutralization studies: Use neutralizing anti-hST2 antibodies to block IL-33/ST2 signaling in cell culture or animal models to elucidate pathway functions.

• Co-immunoprecipitation: Apply anti-hST2 antibodies to pull down protein complexes to identify novel interaction partners in the signaling pathway.

• ChIP-seq analysis: Combine chromatin immunoprecipitation with anti-ST2 antibodies and sequencing to map downstream transcriptional targets.

• In vivo imaging: Conjugate fluorescent labels or radioisotopes to anti-hST2 antibodies for non-invasive tracking of ST2 expression in animal models.

• Conditional knockout validation: Use antibodies to confirm protein depletion in conditional knockout models targeting the ST2 pathway.

• Tissue microarray analysis: Apply antibodies to tissue microarrays to profile ST2 expression across multiple disease specimens simultaneously.

• Flow cytometry phenotyping: Employ anti-hST2 antibodies to identify and isolate ST2-expressing cell populations for functional analysis.

These approaches provide mechanistic insights into how the IL-33/ST2 axis contributes to disease pathogenesis and potential therapeutic intervention points .

What are the methodological considerations for using anti-hST2 antibodies in biomarker development?

When developing hST2 as a biomarker using anti-hST2 antibodies, researchers should address these methodological considerations:

• Assay standardization: Develop standardized protocols with calibrated reference materials to ensure consistent quantification across laboratories.

• Analytical validation: Thoroughly evaluate assay performance characteristics including precision, accuracy, sensitivity, specificity, and limits of detection/quantification.

• Pre-analytical variables: Investigate how sample collection, processing, storage conditions, and freeze-thaw cycles affect hST2 measurement.

• Biological variability assessment: Determine normal reference ranges and account for variables like age, sex, and circadian rhythms that may influence hST2 levels.

• Clinical validation: Correlate hST2 measurements with clinical outcomes in well-characterized patient cohorts.

• Comparative analysis: Benchmark new anti-hST2 antibody-based assays against established methods.

• Multiplex compatibility: Assess whether anti-hST2 antibodies perform reliably in multiplex platforms without cross-reactivity.

• Point-of-care adaptation: Evaluate antibody stability and performance in simplified formats suitable for rapid testing.

These considerations are essential for translating basic research findings into clinically useful biomarker applications for diseases such as cancer, pneumonia, and cardiovascular conditions where ST2 has shown biomarker potential .

How can researchers distinguish between membrane-bound ST2L and soluble ST2 in experimental systems?

Distinguishing between membrane-bound ST2L and soluble ST2 forms in experimental systems requires specific methodological approaches:

• Epitope-specific antibodies: Select antibodies recognizing epitopes unique to each form or shared between forms, depending on experimental goals.

• Subcellular fractionation: Separate membrane fractions from soluble cytosolic and extracellular fractions before antibody detection.

• Domain-specific detection: Use antibodies targeting the transmembrane domain present only in ST2L or the cleaved portion specific to soluble ST2.

• Size-based separation: Employ Western blotting with appropriate molecular weight markers to distinguish the different-sized forms (ST2L is approximately 63-70 kDa while soluble ST2 is approximately 37-40 kDa).

• Cell surface labeling: Conduct non-permeabilized immunostaining to specifically detect membrane-bound ST2L.

• ELISA platform design: Develop sandwich ELISA systems with capture and detection antibodies specifically configured to detect soluble ST2.

• Flow cytometry analysis: Combine membrane integrity dyes with anti-ST2 antibodies to differentiate between surface and intracellular populations.

These approaches allow researchers to specifically track and quantify the distinct forms of ST2, which is critical for understanding their differential roles in the IL-33/ST2 signaling axis and disease processes .

How might anti-hST2 antibodies be utilized in studying the relationship between ST2 and other inflammatory pathways?

Anti-hST2 antibodies can be instrumental in exploring the intersection between ST2 and other inflammatory pathways through these approaches:

• Multiplex co-localization: Combine anti-hST2 antibodies with antibodies against other inflammatory mediators in imaging studies to identify cells co-expressing multiple pathway components.

• Sequential immunoprecipitation: Use anti-hST2 antibodies in sequential pull-down experiments to identify complex formation with components of other signaling cascades.

• Proximity ligation assays: Apply antibody-based proximity techniques to visualize and quantify molecular interactions between ST2 and other inflammatory proteins in situ.

• Phospho-specific detection: Combine anti-hST2 antibodies with phospho-specific antibodies to monitor how ST2 signaling affects activation states of other pathways.

• Transcriptional profiling: Use anti-hST2 antibodies to isolate ST2-expressing cells for subsequent analysis of global inflammatory gene expression patterns.

• Cytokine release assays: Employ blocking anti-hST2 antibodies to determine how ST2 inhibition affects the production of cytokines from other inflammatory pathways.

• Single-cell analysis: Integrate anti-hST2 antibody labeling with single-cell technologies to map pathway interactions at unprecedented resolution.

These approaches help decipher the complex regulatory networks connecting ST2 with other inflammatory mediators, potentially revealing novel therapeutic targets and intervention strategies .

What methodological approaches can researchers use to study the regulation of soluble versus membrane-bound ST2 expression?

To investigate the regulatory mechanisms governing the balance between soluble and membrane-bound ST2 expression, researchers can employ these methodological approaches:

• Promoter analysis: Use chromatin immunoprecipitation with anti-transcription factor antibodies followed by anti-hST2 antibody detection to identify factors regulating different ST2 isoforms.

• Alternative splicing assessment: Design RT-PCR primers and antibodies that distinguish splice variants to monitor differential expression under various conditions.

• Pulse-chase experiments: Combine metabolic labeling with anti-hST2 immunoprecipitation to track the kinetics of ST2L production and conversion to soluble forms.

• Protease inhibition studies: Apply specific protease inhibitors while monitoring soluble ST2 levels using anti-hST2 antibodies to identify enzymes responsible for ST2L cleavage.

• Domain-specific mutagenesis: Create ST2 constructs with mutations in potential regulatory regions, then use antibodies to monitor how these affect the membrane-bound/soluble ratio.

• Stimulation time courses: Treat cells with various stimuli and use anti-hST2 antibodies to track temporal changes in the expression of different ST2 forms.

• Subcellular trafficking analysis: Employ antibody-based microscopy techniques to visualize the intracellular routing of ST2 forms through secretory and endocytic pathways.

These approaches help elucidate the molecular mechanisms controlling the balance between ST2 forms, which is crucial for understanding how this balance is dysregulated in disease states .

How should researchers address contradictory results from different anti-hST2 antibody clones?

When faced with contradictory results from different anti-hST2 antibody clones, researchers should implement these systematic validation approaches:

• Epitope mapping: Determine the precise epitopes recognized by each antibody clone to understand if differences stem from detecting distinct regions of the ST2 protein.

• Knockout validation: Test antibodies on samples from ST2 knockout models to confirm specificity and rule out off-target binding.

• Orthogonal method verification: Validate findings using non-antibody-based methods such as mass spectrometry or mRNA analysis.

• Cross-validation with multiple antibodies: Use multiple antibody clones targeting different epitopes to build consensus results.

• Standardized positive controls: Implement consistent positive control samples to benchmark antibody performance across experiments.

• Batch effect analysis: Evaluate whether contradictions correlate with antibody lot numbers or experimental timing.

• Condition-dependent epitope accessibility: Investigate whether experimental conditions affect epitope exposure differently for different antibody clones.

• Publication bias assessment: Systematically review published literature for each antibody clone to identify consistent patterns of reliability.

What quantitative considerations should researchers address when measuring hST2 levels in biological samples?

Accurate quantification of hST2 levels in biological samples requires addressing these critical quantitative considerations:

• Dynamic range determination: Establish the range of linear detection for each antibody-based assay and ensure sample measurements fall within this range.

• Standard curve optimization: Develop standard curves using recombinant hST2 with confirmed concentration and purity, including sufficient data points for accurate interpolation.

• Limit of detection/quantification: Empirically determine the lower limits of detection and quantification for each assay protocol.

• Dilution linearity: Verify that serially diluted samples produce proportional measurements to confirm absence of matrix effects.

• Spike recovery assessment: Add known quantities of recombinant hST2 to samples to determine percent recovery and identify potential interferents.

• Inter-assay and intra-assay variation: Calculate coefficients of variation for repeated measurements to establish assay precision.

• Biological reference intervals: Establish normal reference ranges from appropriate control populations stratified by relevant variables.

• Pre-analytical variable control: Standardize sample collection, processing, and storage to minimize variability from non-biological factors.

Addressing these quantitative considerations ensures that reported hST2 measurements accurately reflect true biological levels, enabling meaningful comparisons across studies and reliable biomarker development .

How might anti-hST2 antibodies contribute to developing targeted therapeutics for inflammatory and oncological conditions?

Anti-hST2 antibodies have significant potential to contribute to therapeutic development through these research applications:

• Therapeutic target validation: Use antibody-mediated neutralization to confirm ST2's role in disease models before developing therapeutic candidates.

• Antibody-drug conjugate (ADC) development: Conjugate cytotoxic payloads to anti-hST2 antibodies to selectively target ST2-expressing cancer cells.

• Bi-specific antibody engineering: Create antibodies targeting both ST2 and immune effector cells to redirect immune responses to diseased tissues.

• Pharmacokinetic/pharmacodynamic (PK/PD) modeling: Employ antibody-based detection to monitor how experimental therapeutics affect ST2 expression and signaling over time.

• Companion diagnostic development: Develop antibody-based assays to identify patients most likely to benefit from IL-33/ST2-targeted therapies.

• Antibody humanization: Modify research-grade antibodies through humanization processes to develop potential therapeutic candidates.

• Patient stratification biomarker: Utilize anti-hST2 antibodies in clinical sample testing to identify disease subtypes that might respond differently to targeted therapies.

These approaches leverage anti-hST2 antibodies as both research tools and potential therapeutic agents, accelerating the translation of basic IL-33/ST2 biology into clinical applications .

What methodological innovations might enhance the utility of anti-hST2 antibodies in single-cell analysis techniques?

Emerging methodological innovations that could enhance anti-hST2 antibody applications in single-cell analysis include:

• Antibody barcoding techniques: Conjugate unique DNA barcodes to anti-hST2 antibodies for high-dimensional single-cell protein analysis compatible with sequencing platforms.

• Mass cytometry adaptation: Develop metal-conjugated anti-hST2 antibodies for CyTOF analysis to enable simultaneous detection of dozens of proteins alongside ST2.

• Spatial transcriptomics integration: Combine anti-hST2 antibody staining with spatial transcriptomics to correlate protein expression with transcriptional profiles in tissue contexts.

• Microfluidic antibody cycling: Implement iterative antibody staining and elution in microfluidic devices to increase multiplexing capabilities while maintaining single-cell resolution.

• Live-cell antibody reporters: Develop non-disruptive anti-hST2 antibody fragments for real-time monitoring of ST2 dynamics in living cells.

• Single-molecule imaging: Apply super-resolution microscopy with fluorescently labeled anti-hST2 antibodies to visualize nanoscale protein organization.

• Antibody-based lineage tracing: Use photoactivatable anti-hST2 antibodies to track the fate of ST2-expressing cells over time in complex tissues.

These innovations promise to reveal unprecedented details about ST2 biology at single-cell resolution, providing deeper insights into heterogeneity in immune responses and disease processes .